Broluczimab improves persistent macular fluid in previously treated wet AMD eyes
Switching to broluczimab after prior treatment with aflibercept or bevacizumab significantly reduced intraretinal and subretinal fluid in eyes with neovascular age-related macular degeneration (wet AMD), according to real-world data presented at the 2021 ASRS Annual Meeting.
In this retrospective case series, 48 eyes with wet AMD that had been previously treated with aflibercept (IVA-IVBr group) and 10 eyes with wet AMD that had been previously treated with bevacizumab (IVBe-IVBr group), were switched to broluczimab due to persistent fluid after ≥3 prior anti-VEGF injections. There was a mean of 6 weeks between the last injection and the first injection of broluczimab.
In eyes switched from aflibercept to broluczimab, after a mean of 6 weeks post-initial injection, mean central subfield thickness (CSFT) improved from 340 to 305 mm (P < 0.001). At this time, 31% of eyes had no fluid, 42% had reduced fluid, 25% had stable fluid, and 2% had increased fluid. In the 26 eyes that had 3 broluczimab injections, mean CSFT went from 325 to 277 mm (P = 0.001) and 24% of eyes had no fluid at the last follow-up visit.
In eyes switched from bevacizumab to broluczimab, after a mean of 6 weeks post-initial injection, CSFT improved from 401 to 325 mm (P = 0.009). At this time, 30% of eyes had no fluid and 70% had reduced fluid. In the 4 eyes that had 3 broluczimab injections, mean CSFT went from 375 to 275 mm (P = 0.001) and 50% of eyes had no fluid at the last follow-up visit.
In the IVA-IVBr group, mean logMAR at baseline was 0.44 and at the fourth visit was 0.40. in the IVBe-IVBr group, it was 0.33 and 0.35, respectively.
Hussain RM, et al. Real World Experience of Brolucizumab for Persistent Macular Fluid in Neovascular Age-Related Macular Degeneration After Prior Anti-VEGF Treatments. Presented at: 2021 ASRS Annual Meeting.